

HR 3742

Antibiotic Development to Advance Patient Treatment Act of 2013

Congress: 113 (2013–2015, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 12, 2013

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Dec 13, 2013)

Official Text: <https://www.congress.gov/bill/113th-congress/house-bill/3742>

Sponsor

Name: Rep. Gingrey, Phil [R-GA-11]

Party: Republican • **State:** GA • **Chamber:** House

Cosponsors (52 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Blackburn, Marsha [R-TN-7]	R · TN		Dec 12, 2013
Rep. Butterfield, G. K. [D-NC-1]	D · NC		Dec 12, 2013
Rep. DeGette, Diana [D-CO-1]	D · CO		Dec 12, 2013
Rep. Engel, Eliot L. [D-NY-16]	D · NY		Dec 12, 2013
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		Dec 12, 2013
Rep. Green, Gene [D-TX-29]	D · TX		Dec 12, 2013
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Dec 12, 2013
Rep. Shimkus, John [R-IL-15]	R · IL		Dec 12, 2013
Rep. Whitfield, Ed [R-KY-1]	R · KY		Dec 12, 2013
Rep. Barrow, John [D-GA-12]	D · GA		Mar 24, 2014
Rep. Cassidy, Bill [R-LA-6]	R · LA		Mar 24, 2014
Rep. Dingell, John D. [D-MI-12]	D · MI		Mar 24, 2014
Rep. Ellmers, Renee L. [R-NC-2]	R · NC		Mar 24, 2014
Rep. Lance, Leonard [R-NJ-7]	R · NJ		Mar 24, 2014
Rep. Latta, Robert E. [R-OH-5]	R · OH		Mar 24, 2014
Rep. Matheson, Jim [D-UT-4]	D · UT		Mar 24, 2014
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Mar 24, 2014
Rep. Olson, Pete [R-TX-22]	R · TX		Mar 24, 2014
Rep. Pompeo, Mike [R-KS-4]	R · KS		Mar 24, 2014
Rep. Tonko, Paul [D-NY-20]	D · NY		Mar 24, 2014
Rep. Yarmuth, John A. [D-KY-3]	D · KY		Mar 24, 2014
Rep. Guthrie, Brett [R-KY-2]	R · KY		Apr 28, 2014
Rep. Lujan, Ben Ray [D-NM-3]	D · NM		Apr 28, 2014
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		May 8, 2014
Rep. Shea-Porter, Carol [D-NH-1]	D · NH		May 28, 2014
Rep. Speier, Jackie [D-CA-14]	D · CA		May 28, 2014
Rep. McMorris Rodgers, Cathy [R-WA-5]	R · WA		Jul 9, 2014
Rep. Roskam, Peter J. [R-IL-6]	R · IL		Jul 10, 2014
Rep. McCaul, Michael T. [R-TX-10]	R · TX		Jul 15, 2014
Rep. Barton, Joe [R-TX-6]	R · TX		Jul 17, 2014
Rep. Langevin, James R. [D-RI-2]	D · RI		Jul 17, 2014
Rep. Byrne, Bradley [R-AL-1]	R · AL		Jul 22, 2014
Rep. McNerney, Jerry [D-CA-9]	D · CA		Jul 22, 2014
Rep. Roe, David P. [R-TN-1]	R · TN		Jul 22, 2014
Rep. Pascrell, Bill, Jr. [D-NJ-9]	D · NJ		Jul 29, 2014
Rep. Johnson, Eddie Bernice [D-TX-30]	D · TX		Jul 30, 2014
Rep. Heck, Joseph J. [R-NV-3]	R · NV		Sep 8, 2014
Rep. DesJarlais, Scott [R-TN-4]	R · TN		Sep 9, 2014
Rep. Ellison, Keith [D-MN-5]	D · MN		Sep 11, 2014
Rep. Kilmer, Derek [D-WA-6]	D · WA		Sep 11, 2014
Rep. Conaway, K. Michael [R-TX-11]	R · TX		Sep 15, 2014

Cosponsor	Party / State	Role	Date Joined
Rep. Flores, Bill [R-TX-17]	R · TX		Sep 15, 2014
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		Sep 16, 2014
Rep. Joyce, David P. [R-OH-14]	R · OH		Sep 16, 2014
Rep. Scott, Austin [R-GA-8]	R · GA		Sep 16, 2014
Rep. Takano, Mark [D-CA-41]	D · CA		Sep 16, 2014
Rep. Tipton, Scott R. [R-CO-3]	R · CO		Sep 16, 2014
Rep. Harper, Gregg [R-MS-3]	R · MS		Nov 12, 2014
Rep. Rogers, Mike J. [R-MI-8]	R · MI		Nov 12, 2014
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Nov 12, 2014
Rep. Cartwright, Matt [D-PA-17]	D · PA		Nov 19, 2014
Rep. Brownley, Julia [D-CA-26]	D · CA		Nov 20, 2014

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Dec 13, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Antibiotic Development to Advance Patient Treatment Act of 2013 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to authorize the Secretary of Health and Human Services (HHS) to approve the use of an antibacterial or antifungal drug that is intended for treatment of a serious or life-threatening disease or condition to treat a limited population of patients for which there is an unmet medical need.

Requires the labeling of such drugs to prominently include in the prescribing information the statement that the drug is indicated for use in a limited and specific population of patients.

Amends the Public Health Service Act to authorize the Secretary to license those antibacterial or antifungal drugs as biological products.

Requires the Secretary, acting through the Director of the Centers for Disease Control and Prevention (CDC), to: (1) monitor the use of antibacterial and antifungal drugs, (2) monitor changes in bacterial and fungal resistance to drugs, and (3) make the information derived from such monitoring available to the public.

Amends the FFDCA to direct the Secretary: (1) to identify upon approval, and subsequently update, susceptibility test interpretive criteria for antibacterial drugs by relying upon preclinical and clinical data, Bayesian and pharmacometric statistical methodologies, and such other confirmatory evidence the Secretary deems necessary; (2) on a quarterly basis, to evaluate new or updated criteria published by a nationally or internationally recognized standard development organization; and (3) to publish on the Food and Drug Administration's (FDA's) website a notice adopting, declining to adopt, or partially adopting such new or updated criteria.

Actions Timeline

- **Dec 13, 2013:** Referred to the Subcommittee on Health.
- **Dec 12, 2013:** Introduced in House
- **Dec 12, 2013:** Referred to the House Committee on Energy and Commerce.